EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy

T Kumai*,1,2, Y Matsuda1, K Oikawa1, N Aoki1, S Kimura1, Y Harabuchi2, E Celis3 and H Kobayashi*,1

1Department of Pathology, Asahikawa Medical University, Asahikawa, Japan; 2Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Japan and 3H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

Background: Head and neck squamous cell carcinoma (HNSCC) is a major cause of cancer-related morbidity and mortality worldwide. Epidermal growth factor receptor (EGFR)-targeted therapy is an attractive strategy alternative to conventional cancer treatments for HNSCC, but its efficacy remains controversial. T-cell-based immunotherapy has been proposed as a novel therapeutic approach to improve the clinical outcome for HNSCC. In this study, we report human epidermal receptor (HER) family epitopes that induced CD4 T-cell responses to HNSCC. The results provide support for a novel strategy to treat HNSCC by combining EGFR-targeted therapy with T-cell-based immunotherapy.

Methods: We evaluated the capacity of predicted CD4 T-cell peptide epitopes from EGFR to induce antitumour immune responses in vitro. In addition, EGFR inhibitors were evaluated for their ability to augment tumour MHC class II expression in HNSCC cell lines and subsequently increase T-cell recognition.

Results: Among several predicted peptide epitopes, EGFR875–889 elicited CD4 T-cell responses that were restricted by HLA-DR4, DR15, or DR53 molecules, indicating that the peptide functions as a promiscuous T-cell epitope. The peptide-reactive T cells responded to autologous dendritic cells loaded with EGFR-expressing tumour cell lysates, indicating that these epitopes are naturally processed. In addition, the CD4 T cells were capable of directly recognising and killing HNSCC cells expressing EGFR and the appropriate HLA class II molecule. T cells reactive with the EGFR875–889 epitope could be detected in the blood of HNSCC patients. EGFR875–889-reactive CD4 T cells were also able to recognise several peptide analogues derived from homologous regions of EGFR family members, HER-2, HER-3 and c-MET. Finally, we examined the effects of EGFR tyrosine kinase inhibition or EGFR-blocking antibodies on CD4 T-cell tumour reactivity. Treatment of tumour cells with the EGFR inhibitors enhanced tumour recognition by EGFR875–889-reactive T cells presumably due to the upregulation of HLA-DR expression in the HNSCC cells.

Conclusion: We identified novel CD4 T-cell EGFR epitopes and amongst these, EGFR875–889 functions as a promiscuous helper T-cell epitope that can elicit effective antitumour T-cell responses against tumours expressing HER family members and c-MET. These observations should facilitate the translation of T-cell-based immunotherapy into the clinic for the treatment of HNSCC and provide a rational basis for EGFR inhibition, immune-targeted combination therapy.
and distant metastases are common in patients with locally advanced disease who have received conventional therapy (Michiels et al, 2009). Thus, there is an urgent need to broaden and improve the treatment options for HNSCC.

The epidermal growth factor receptor (EGFR) has an important role in oncogenesis in many kinds of malignancies including HNSCC by enhancing cell proliferation and inhibiting apoptosis (Del Vecchio et al, 2012). Moreover, EGFR overexpression has been used as an independent prognostic indicator for HNSCC patients (Wheeler et al, 2012). To inhibit EGFR signalling, EGFR-targeted therapies such as the use of antagonistic antibodies and tyrosine kinase inhibitors (TKIs) have been introduced to the clinical oncology practice. The addition of an anti-EGFR antibody (cetuximab) to radiation therapy (RT) significantly improved median overall survival and median duration of loco-regional control compared with RT-alone in patients with locally advanced HNSCC (Bonner et al, 2006). Similarly, the use of erlotinib (an EGFR TKI) prolonged disease stabilisation in a heavily pretreated HNSCC patient population (Soulieres et al, 2004). Despite these promising results, these therapies did not lead to durable remissions mostly due to innate and acquired resistance to the EGFR inhibitors (Diaz et al, 2012).

Recently, it has been reported that EGFR blockers may overcome the inhibitory effect of EGFR signalling to CIITA, resulting in increased MHC expression on HNSCC cells (Pollack et al, 2011). In view of this, we hypothesise that the overall efficacy of EGFR inhibitor-targeted therapy in HNSCC patients could be enhanced by the addition of T-cell-based immunotherapy, which could also be directed towards the EGFR molecule. There is little doubt that effective antitumour immunotherapy will require the coordinate participation of both CD4 (helper) and CD8 (cytotoxic) T-cell responses. Although considerable work has been devoted towards the identification of CD8 cytotoxic T lymphocyte (CTL) epitopes from EGFR (Shomura et al, 2004), little effort has been directed to identify EGFR peptide epitopes recognised by CD4 T helper lymphocytes (HTLs). In addition to being critical for the generation and persistence of CTLs, HTLs can also function as effector cells by exhibiting direct antitumour cytotoxic activity against MHC class II (MHC-II)-expressing tumours (Hahn et al, 1995). Here, we describe several novel EGFR peptide epitopes that were capable of eliciting antigen-specific and HLA-DR-restricted CD4 T-cell responses against EGFR-expressing HNSCC cells. Interestingly, one of these epitopes (EGFR875–889) was shown to induce HTLs that crossreacted with the analogous corresponding HER-2, HER-3 and c-Met peptides and tumour cell lines expressing these antigens. Treatment of HNSCC tumours with EGFR inhibitors (erlotinib and cetuximab) resulted in enhanced antitumour recognition by the EGFR-reactive CD4 helper T cells owing to the upregulation of tumour MHC-II molecules. Overall, these results suggest that EGFR-encoded T helper epitopes, some which may be crossreactive towards the homologous HER-2, HER-3 and c-Met regions, may be utilised in vaccination strategies that could be combined with EGFR blockade for a more effective treatment of HNSCC.
autologous purified CD4 T cells in 96-well flat-bottomed culture plates. One week after peptide stimulation, the CD4 T cells were restimulated in individual microcultures with peptide-pulsed irradiated autologous PBMCs and 2 days later, recombinant human IL-2 was added at a final concentration of 10 IU ml⁻¹. One week later, the T cells were tested for antigen reactivity using a cytotoxic-release assay as described below. These microcultures exhibiting a significant response of cytotoxic-release to peptide (at least 2.5-fold over background) were cloned by limiting dilution and expanded in 24-well plates by weekly restimulation with peptides and irradiated autologous PBMCs. Complete culture medium for all procedures consisted of AIM-V medium (Invitrogen/GIBCO, Carlsbad, CA, USA) supplemented with 3% human male AB serum. All blood samples were obtained after the appropriate informed consent.

Measurement of antigen-specific responses with established CD4 T-cell clones. CD4 T cells (3 × 10⁶ per well) were mixed with irradiated antigen-presenting cells (APCs) in the presence of various concentrations of antigen (peptides, tumour lysates) in 96-well culture plates. APCs consisted of autologous PBMCs (1 × 10⁶ per well), HLA-DR-expressing L-cells (3 × 10⁵ per well), autologous DCs (5 × 10⁵ per well) or tumour cell lines (3 × 10⁵ per well). The HNSCC cell lines were previously treated with IFN-γ at 500 U ml⁻¹ for 48 h to enhance HLA-DR expression. To examine the role of EGFR inhibitor in augmenting the expression of MHC-II molecules, HNSCC cell lines were preincubated with or without 100 ng ml⁻¹ DMSO, EGFR TKI, erlotinib (tyrosine kinase reversible inhibitor, 1 μM, Selleck chemicals, Houston, TX, USA), EGFR antagonistic antibody cetuximab (2 μg ml⁻¹, Merck AG, Zug, Switzerland) or bevacizumab (2 μg ml⁻¹, Roche, Istanbul) for 2 h at 37°C before addition of IFN-γ. The expression of HLA-DR molecules, EGFR, HER-2, HER-3 and c-MET on tumour cells were evaluated by flow cytometry using anti-HLA-DR mAb conjugated with fluorescein isothiocyanate, anti-EGFR mAb conjugated with phycoerythrin (BD Pharmingen, San Diego, CA, USA), anti-HER-2 mAb conjugated with phycoerythrin, anti-HER-3 mAb conjugated with phycoerythrin (Bielegend, San Diego, CA, USA) and anti-c-MET conjugated with phycoerythrin (R&D Systems, Minneapolis, MN, USA), respectively. Tumour cell lysates were prepared by three freeze–thaw cycles of 1 × 10⁸ tumour cells, resuspended in 1 ml of serum-free AIM-V medium. Tumour cell lysates served as an antigen at 5 × 10⁵ cell equivalents per ml. Culture supernatants were collected after 48 h for measuring antigen-induced lymphokine (IL-4, IFN-γ, and GM-CSF) production by the CD4 T cells using ELISA kits (BD Pharmingen). To demonstrate antigen-specificity and HLA-DR restriction, CD4 T cells responses were blocked by adding anti-HLA-DR mAb L243 (lgG2a prepared from supernatants of the hybridoma HB-55 obtained from the ATCC) or the anti-HLA-A/B/C mAb W6/32 (lgG2a, ATCC) at 10 μg ml⁻¹ throughout the 48-h incubation period.

Cell-mediated cytotoxicity assays. Cytotoxic activity of CD4 T cell clones was measured using a colorimetric CytoTox 96 assay (Promega, Madison, WI, USA). This system quantifies the release of lactate dehydrogenase (LDH) from target cells. T cells were mixed with 2 × 10⁶ target cells at different effector to target (E:T) ratios in 96-well round-bottomed plates. After 6 h incubation at 37°C, 50 μl supernatant samples were collected from each well to measure LDH content.

Measurement of peptide-specific responses in HNSCC patients. PBMCs were isolated from fresh heparinized blood by Ficoll-Conray centrifugation and washed twice with RPMI 1640. PBMCs were resuspended in complete medium and placed at 1.5 × 10⁸ cells per well and cultured in triplicate in 96-well round-bottomed plates in the presence of 10 μg ml⁻¹ peptide. Negative controls (in the absence of peptide) were prepared in eight replicate samples. One week later, the cultures were restimulated with peptide-pulsed (10 μg ml⁻¹) irradiated autologous PBMCs (5 × 10⁶ per well). After 7 days of restimulation, supernatants were harvested for examining the ability of peptide-induced lymphokine production (IL-4, IFN-γ and GM-CSF) by the HNSCC patient’s PBMCs. The institutional ethics committee had approved the study protocol (approval number 1066) and the appropriate written informed consent for blood donation was obtained from all patients and healthy donors before blood sampling.

Selection of potential HLA class II-restricted EGFR peptide epitopes. The identification of promiscuous HLA class II-binding peptide epitopes would be advantageous for the design of T-cell epitope-based vaccines for a broad cancer patient population. To predict promiscuous HLA class II-binding peptides, we used computer-based MHC-II peptide-binding algorithms for three common HLA class II molecules, HLA-DR1, DR4 and DR7 (Southwood et al, 1998). Using these algorithms the peptides that score high for binding to DR1, DR4 and DR7 demonstrated high capacity to bind to additional HLA class II alleles such as DR9, DR13, DR15 and DR53 (Kobayashi and Celis, 2008). Utilising this prediction system with the EGFR sequence, we selected peptides, EGFR85-99 (VAGYVLIALNTVERI), EGFR875-889 (KVPIKWMA) and EGFR1136-1150 (VPKWKMALESILHR) and EGFR1136-1150 (PEYLTNVQPTCVNST), which exhibited the highest combined binding scores to all three HLA class II alleles (data not presented).

Induction of CD4 T-cell responses to EGFR peptide epitopes. We synthesised the three potential EGFR peptide epitopes and proceeded to study whether these peptides could induce CD4 helper T-cell responses in vitro. PBMCs were obtained from four healthy MHC-II typed individuals (donor 1 ‘S; HLA-DR4/15, donor 2 ‘H; HLA-DR4/9, donor 3 ‘T; HLA-DR9/12 and donor 4 ‘M; HLA-DR9/13) to select CD4 T cells and prepare autologous DCs, which were used as APCs. After three peptide restimulation cycles, peptides (EGFR85-99, EGFR875-889 and EGFR1136-1150) were able to induce peptide-reactive CD4 T-cell responses in all of the four donors. As shown in Figure 1A, peptide dose titration curves showed that the affinity of the CD4 T cells from all four donors for peptide EGFR875-889 was substantially higher as compared with the T cells reactive with peptides EGFR85-99 and EGFR1136-1150. These results suggest that amongst the three potential CD4 T-cell epitopes, EGFR875-889 could be the most effective peptide for inducing antigen-specific CD4 T-cell responses capable of recognising tumour cells. In addition, the amino-acid sequence of EGFR875-889 is similar with the homologous regions of the HER-2, HER-3 and c-Met proteins (Table 1). Thus, we decided to focus our research effort on EGFR875-889 to further evaluate its ability to elicit tumour-reactive CD4 T cells. To carry out tumour recognition and fine MHC restriction analysis, we isolated T-cell clones from the EGFR875-889 reactive CD4 T-cell lines of the four normal blood donors. As shown in Figure 1B, the response to EGFR875-889 peptide observed with T-cell clones, S11 and S22 (from donor 1), H22 (donor 2), T8 (donor 3) and M8 (donor 4) was mediated via MHC-II, as this recognition was inhibited by antibody L243 (but not by the w6/32 anti-HLA class I antibody). As the L243 antibody is specific for HLA-DR and does not react with other MHC-II molecules (HLA-DR, -DP, -DQ), these results indicate that the presentation of EGFR peptide epitopes to the CD4 T-cell clones is via HLA-DR molecules. Next, to identify the HLA-DR restriction alleles for the EGFR875-889 epitope, we assessed the T-cell responses using a panel of HLA-DR-transfected mouse L-cells as APCs. As shown in Figure 1C, T-cell clone S11 was
restricted by HLA-DR15, whereas clones M8, T8, and H22 were restricted by HLA-DR53 and clone S22 by HLA-DR4. These results indicate that EGFR875–889 can be presented to CD4 T cells by multiple HLA-DR alleles, thus behaving as a classic promiscuous MHC-II epitope.

**Direct recognition of EGFR-expressing HNSCC cells by EGFR875–889-reactive CD4 T cells.** It is important to assess whether peptide-reactive CD4 T cells have the ability to recognise naturally processed antigens directly on MHC-II expressing tumour cells (Kobayashi and Celis, 2008). Furthermore, in some instances CD4 T cells have the capacity to kill the tumour cells in an antigen-specific and MHC-II-restricted manner (Hayashi et al, 2011). In view of this, we studied whether the EGFR875–889-reactive CD4 T-cell clones could directly recognise HLA-DR matching EGFR-positive HNSCC cells as APCs. Before performing these experiments, we assessed the expression of EGFR protein and surface MHC-II molecules in several HNSCC cell lines. As shown in Figure 2A, EGFR was expressed on all eight HNSCC cell lines. On the other hand, the Jurkat T-cell lymphoma did not express the EGFR and therefore was used for future studies as a negative control. With the exception of two HNSCC cell lines (CA9-22 and Ho-1-u-1) and Jurkat, six HNSCC cell lines expressed HLA-DR as matching EGFR-positive HNSCC cells as APCs. Before performing these experiments, we assessed the expression of EGFR protein and surface MHC-II molecules in several HNSCC cell lines. As shown in Figure 2A, EGFR was expressed on all eight HNSCC cell lines. On the other hand, the Jurkat T-cell lymphoma did not express the EGFR and therefore was used for future studies as a negative control. With the exception of two HNSCC cell lines (CA9-22 and Ho-1-u-1) and Jurkat, six HNSCC cell lines expressed HLA-DR as matching EGFR-positive HNSCC cells as APCs. Before performing these experiments, we assessed the expression of EGFR protein and surface MHC-II molecules in several HNSCC cell lines. As shown in Figure 2A, EGFR was expressed on all eight HNSCC cell lines. On the other hand, the Jurkat T-cell lymphoma did not express the EGFR and therefore was used for future studies as a negative control. With the exception of two HNSCC cell lines (CA9-22 and Ho-1-u-1) and Jurkat, six HNSCC cell lines expressed HLA-DR as matching EGFR-positive HNSCC cells as APCs. Before performing these experiments, we assessed the expression of EGFR protein and surface MHC-II molecules in several HNSCC cell lines. As shown in Figure 2A, EGFR was expressed on all eight HNSCC cell lines. On the other hand, the Jurkat T-cell lymphoma did not express the EGFR and therefore was used for future studies as a negative control. With the exception of two HNSCC cell lines (CA9-22 and Ho-1-u-1) and Jurkat, six HNSCC cell lines expressed HLA-DR as matching EGFR-positive HNSCC cells as APCs. 

**Figure 1. Induction of CD4 T-cell responses using predicted peptide epitopes derived from EGFR.** (A) CD4 T-cell responses against candidate EGFR peptide epitopes were elicited from four healthy individuals and were subsequently tested for their capacity to recognise various concentrations of peptides presented by autologous PBMCs. Points, mean of triplicate determinations, bars s.d. Points without bars had s.d. <10% the value of the mean. Results are representative of three experiments that were performed with the same samples. (B) Anti-HLA-DR mAb L243 (10 μg ml⁻¹) inhibited IFN-γ production from EGFR875–889-reactive CD4 T-cell clones. Anti-HLA Class I antibody was used as control. (C) IFN-γ productions of EGFR875–889-reactive CD4 T-cell clones were evaluated using L-cells as APCs to define the restricting HLA-DR elements. Columns means of triplicate determinations, bars s.d. Columns without bars had s.d. <10% the values of the mean. Results are representative of at least two experiments.

### Table 1. Peptide sequences of EGFR875–889 and its homologous HER family and c-Met analogue peptide

| Peptide          | Sequence         |
|------------------|------------------|
| EGFR875–889      | KVPIKWMALESILHR  |
| HER-2:833–897    | KVPIKWMALESLRR   |
| HER-3:722–886    | KTPIKWMALESILFG  |
| c-Met1:1244–1258 | KLIPKWALESILGQTQ |

Underlined and bold letters indicate amino acids that are different from peptide EGFR875–889.
processed peptide epitope was presented via HLA-DR expressed on the tumour cells. Tumour cell lines that did not express the appropriate antigen or the corresponding matched HLA-DR molecule failed to stimulate the CD4 T cells, demonstrating that direct tumour recognition by the T-cell clones was both antigen-specific and HLA-DR-restricted.

Next, we evaluated the cytotoxic activity of the EGFR875–889-reactive CD4 T-cell clones against the HNSCC tumour cells. As shown in Figure 3B, three of the CD4 T-cell clones, S11 (DR15-restricted), H22 (DR53-restricted) and T8 (DR53-restricted), effectively lysed EGFR-expressing HNSCC cell lines in a dose-dependent manner. On the other hand, clones M8 (DR53-restricted) and S22 (DR4 restricted) were unable to kill MHC-II-matched HNSCC cells (data not shown). Taken together, these results illustrate that EGFR peptide-reactive CD4 T-cell clones not only recognise EGFR-expressing tumours but some also have the ability to kill tumour cells directly.

Recognition of naturally processed exogenous antigen by EGFR-reactive CD4 T-cell clones. Having observed the reactivity of the CD4 T-cell clones to EGFR875–889 peptide (Figure 1) and directly on tumour cell lines (Figure 3), we next assessed the capacity of professional APCs such as DCs to capture and process antigens derived from dead EGFR-expressing tumour cells and to present the EGFR epitope to the CD4 T-cell clones. Autologous DCs were pulsed with tumour cell freeze–thaw lysates and subsequently evaluated as APCs with the EGFR 875–889-reactive CD4 T-cell clones. To eliminate the possibility that tumour-derived MHC-II peptide complexes within the lysate would directly stimulate the T cells, lysates were prepared using EGFR-expressing MHC-II-mismatched tumours. As shown in Supplementary Figure 1, T-cell clones S11 and H22 specifically recognised naturally processed antigen presented by DCs in a HLA-DR-restricted manner, as these responses were inhibited by anti-HLA-DR mAb and were not detected using DCs loaded with
Figure 3. Direct recognition of EGFR expressing HNSCC by EGFR<sub>875–889</sub> reactive CD4 T-cell clones. (A) EGFR<sub>875–889</sub> reactive CD4 T-cell clones were tested for their capacity to recognise antigen directly on EGFR-positive HLA-DR matched or mismatched HNSCC cells by IFN-γ production. The HLA-DR-negative cell line Jurkat was used as negative control. HLA-DR restriction of these responses was demonstrated by blocking tumour recognition with anti-HLA-DR mAb L243 (10 μg ml<sup>−1</sup>). Columns without bars had s.d. < 10% the values of the mean. Results are representative of three separate experiments. (B) EGFR<sub>875–889</sub>-reactive CD4 T-cell clones were evaluated for their capacity to kill EGFR-positive HLA-DR-matched HNSCC cells. HLA-DR unmatched cell lines were used as negative controls. Points, mean of triplicate determinations, bars s.d. Points without bars had s.d. < 10% the value of the mean. Results are representative of three separate experiments.
PBMC lysates (negative control). However, CD4 T-cell clones M8, T8, and S22, which were efficient in directly recognising endogenously processed epitope on tumour cells, were not able to recognise tumour cell lysates presented by DCs (data not shown). One possible explanation for the lack of recognition of tumour lysate pulsed DCs by T-cell clones M8, T8, and S22 could be due to differences in the mode of antigen processing and MHC-II peptide loading between endogenously processed epitopes presented by tumours and the exogenously processed epitopes presented by DCs. Nevertheless, the results demonstrate that CD4 T cells are capable of recognising the EGFR\textsubscript{875–889} presented by several MHC-II molecules, either directly on tumour cells or indirectly by professional APCs loaded with tumour cell lysates.

**EGFR inhibitors augment HLA-DR expression on tumour cell lines.** Important factors that can facilitate tumour escape from immune surveillance can be alterations in the expression of immune-related receptor molecules and cytokines capable of inhibiting immune responses (Katayama et al, 2011; Chuang et al, 2012). Numerous reports have shown that absence or low expression of MHC molecules on tumours can decrease the therapeutic effects of antitumour vaccines (Vertuani et al, 2009). As reduced levels of MHC-I and MHC-II expression induced by EGFR activation have been reported in keratinocytes and HNSCC cell lines (Pollack et al, 2011), we assessed whether EGFR inhibitors influenced the expression of MHC-II in HNSCC cell lines, and consequently affected recognition by T cells. The use of erlotinib, an EGFR tyrosine kinase inhibitor (TKI), augmented HLA-DR expression in several HNSCC cell lines (Figure 4A). Similarly, the EGFR-blocking antibody cetuximab enhanced HLA-DR expression mediated by IFN-\(\gamma\) pre-treatment (Figure 4B). However, HLA-DR expression in SAS, Ho-1-u-1, and HPC-92Y cell lines was not changed with EGFR inhibitors (data not shown). These results suggest that by increasing MHC-II expression, EGFR inhibitors could be used to enhance CD4 T-cell recognition, which could potentiate the antitumour effects of immunotherapy.

**EGFR inhibitors enhance tumour recognition by EGFR\textsubscript{875–889} reactive CD4 T cells.** To assess whether the elevated expression of HLA-DR molecules on tumour cells induced by EGFR inhibitors would result in enhanced antitumor immunity, we co-incubated EGFR\textsubscript{875–889} reactive CD4 T-cell clones with tumour cell lines that were pretreated or not with the EGFR inhibitors. The results presented in Figure 5A and B indicate that overall, the EGFR inhibitors increased recognition of the tumour cells by the CD4 T cells. In one instance, the effects of the EGFR inhibitors was quite dramatic, where the HLA-DR15-restricted CD4 T-cell clone S11 was unable to recognise the CA9-22 (DR15+/EGFR+) tumour unless it was pretreated with the EGFR inhibitors. Further, a potentiating effect of EGFR inhibitors was evident in the recognition of tumour cells by the HLA-DR4-restricted CD4 T-cell clone S22. In addition, the EGFR inhibitors were also shown to increase the cytotoxic activity of the EGFR-reactive S11 CD4 T-cell clone (Figure 5C). These findings suggest that EGFR inhibitors could be used to potentiate CD4 T-cell-based immunotherapy for HNSCC.

**Crossreactivity of EGFR\textsubscript{875–889} reactive CD4 T-cell clones against homologous peptides from various EGFR family members.** EGFR, also known as HER-1, is a member of a family of growth factor receptors that includes HER-2 and HER-3 (Kraus et al, 1989). As previously mentioned, we observed that the sequence of the EGFR\textsubscript{875–889} epitope was highly similar with homologous peptides derived from other members of the HER gene family and c-Met (Table 1). In view of this, we tested whether...
synthetic peptides corresponding to the analogous EGFR<sub>875–889</sub> epitope would be recognised by the various CD4 T-cell clones. As shown in Figure 6A, several degrees of crossreactivity were observed with the CD4 T-cell clones in response to peptides HER-2<sub>883–897</sub>, HER-3<sub>872–886</sub>, and c-Met<sub>1244–1258</sub> whereas the irrelevant (negative control) peptide EZH2<sub>95–109</sub> did not stimulate any of the CD4 T-cell clones. In addition, we observed with the EGFR<sub>875–889</sub>-reactive CD4 T-cell clones in several degrees of crossreactivity were observed with the analogous peptide but clone H22 could not (Figure 6A). The DR15-restricted M8 and T8 clones could crossreact with the c-Met analogue peptide but clone H22 could not (Figure 6A). The DR15-restricted CD4 T-cell clone S11 was used for its capacity to kill EGFR-positive HLA-DR-matched HNSCC cell CA19-9 by cytotoxic assay. CA19-9 was pretreated with Erlotinib (1 mM, square) or cetuximab (2 mg ml<sup>−1</sup>, triangle) for 48 h. Points, mean of triplicate determinations, bars s.d. Points without bars had s.d. <10% the value of the mean. Results are representative of two experiments done with the same samples.

**Figure 5. EGFR inhibitors augmented antitumour responses of EGFR<sub>875–889</sub>-reactive CD4 T-cell clones.** (A) EGFR<sub>875–889</sub>-reactive CD4 T-cell clones were tested for their capacity to recognise antigen directly on EGFR-positive HLA-DR-matched HNSCC cells by IFN-γ production. Tumour cells were pretreated 48 h with or without Erlotinib (1 mM). DMSO was used as negative control. Columns without bars had s.d. <10% the values of the mean. Results are representative of three separate experiments. (B) EGFR<sub>875–889</sub>-reactive CD4 T-cell clones were tested for their capacity to recognise antigen directly on EGFR-positive HLA-DR-matched HNSCC cells by IFN-γ production. Tumor cells were pretreated 48 h with or without cetuximab (2 mg ml<sup>−1</sup>). Anti VEGF antibody bevacizumab was used as negative control. Columns without bars had s.d. <10% the values of the mean. Results are representative of at least two separate experiments. (C) EGFR<sub>875–889</sub>-reactive CD4 T-cell clone S11 was evaluated for its capacity to kill EGFR-positive HLA-DR-matched HNSCC cell CA19-9 by cytotoxic assay. CA19-9 was pretreated with Erlotinib (1 mM, square) or cetuximab (2 mg ml<sup>−1</sup>, triangle) for 48 h. Points, mean of triplicate determinations, bars s.d. Points without bars had s.d. <10% the value of the mean. Results are representative of two experiments that were done with the same samples.

**EGFR peptide recognition by PBMCs from HNSCC patients.** It is important to determine the presence of precursor T cells specific for EGFR peptides in the peripheral blood of HNSCC patients for estimating the potential use of these peptides in cancer vaccines. To evaluate the responses of CD4 T cells from HNSCC patients to EGFR<sub>875–889</sub>, we stimulated PBMCs from five HNSCC patients with the peptide in short-term cultures. As only small volumes of blood from these advanced HNSCC patients were available, we were unable to establish long-term T-cell lines and to perform HLA typing for patients. Tetanus toxin peptide, TT<sub>830–843</sub> was used as a positive control, as this antigen has facility to induce robust CD4 T-cell responses in the majority of people regardless of their HLA-DR alleles. Seven days after the second stimulation, tissue-culture supernatants were collected and amounts of IFN-γ and GM-CSF were measured. In most instances, substantial T-cell responses to EGFR<sub>875–889</sub> were observed in the HNSCC
Figure 6. Responses of EGFR<sub>875–889</sub>-reactive CD4 T-cell clones to EGFR<sub>875–889</sub> analogs and HER-2 or c-Met-expressing tumour cells.

(A) EGFR<sub>875–889</sub>-reactive CD4 T-cell clones were tested for their capacity to recognise EGFR analogue peptides (3 μg ml<sup>−1</sup>) by IFN-γ production. Autologous PBMCs were used as APCs. Columns means of triplicate determinations, bars s.d. Columns without bars had s.d. < 10% the values of the mean. Results are representative of at least two separate experiments. (B) HLA-DR15-restricted EGFR<sub>875–889</sub>-reactive CD4 T-cell clone S11 was tested for the capacity to recognise EGFR-negative HER-2, HER-3 and c-Met positive cell line MCF-7 by IFN-γ production. Anti-HLA-DR mAb L243 (10 μg ml<sup>−1</sup>) was added to demonstrate that T-cell reactivity was through TCR/HLA-DR interaction. Columns means of triplicate determinations, bars s.d. Columns without bars had s.d. < 10% the values of the mean. Results are representative of at least two separate experiments. (C) EGFR and c-Met expression of HNSCC cell line SAS, EBV-LCLs and Jurkat T-cell lymphoma cell lines were examined by western blot. PBMC was used as negative control. (D–F) HLA-DR53-restricted EGFR<sub>875–889</sub>-reactive CD4 T-cell clones were tested for the capacity to recognise EGFR-negative, c-Met-positive cell lines by IFN-γ production. Columns means of triplicate determinations, bars s.d. Columns without bars had s.d. < 10% the values of the mean. Results are representative of at least two separate experiments.
patients (Table 2). These responses were inhibited by anti-HLA-DR mAb, indicating that CD4 T-cell responses were mediated via the T-cell receptor and MHC-II peptide complexes.

**DISCUSSION**

There are many reports documenting the important role that CD4 T cells have in the generation of effective cytotoxic CD8 T-cell responses both against tumours and infectious diseases (Giuntoli et al., 2002). In addition to their helper function, CD4 T cells themselves may exhibit effector cytolytic activity against tumour cells (Hayashi et al., 2011). We believe that the identification of CD4 T helper epitopes will be essential to obtain robust antitumour immunity, as clinical trials using solely CD8 CTLs molecules and CIITA, a transcriptional regulator of MHC class II, can influence the immune response against tumours. (Quesnelle and Grandis, 2011; Grovdal et al., 2012; Huang et al., 2013; Stabile et al., 2013). We have preliminary evidence indicating that HER-2 expression is increased in HNSCC cells following EGFR blockade (unpublished). As HER-2 and c-Met upregulation has been reported in some cancer patients treated with EGFR inhibitors (Suda et al., 2010), the T-cell crossreactivity against HER family and c-Met could expand the candidates for immunotherapy using EGFR875–889 peptide for those EGFR inhibitor-treated patients who develop treatment resistance through HER-2, HER-3, and c-Met upregulation. From these findings, the novel identified EGFR875–889 CD4 T helper peptide epitope might be well-suited for HER family or c-Met combinatorial targeted cancer immunotherapy regardless of EGFR status or resistance to EGFR inhibitors.

The amino-acid sequence of peptide EGFR875–889 in this study is almost identical with peptide HER-2883–897, which differs by only one amino acid near the C terminus end (H888 in EGFR and R898 in HER-2; Table 1). We previously reported that the HER-2883–897 peptide epitope was promiscuously presented in the context of HLA-DR1, DR4, DR5, and DR53 alleles (Kobayashi et al., 2000). In the present study, EGFR875–889-specific CD4 T cells restricted by HLA-DR4 and DR53, but not those restricted by DR15, were able to cross-react with HER-2883–897, suggesting that HER-2883–897 may not bind well to HLA-DR15. Alternatively, it is possible that the T-cell receptor of the EGFR875–889-specific DR15-restricted clone relies on the histidine in position 888 for antigen recognition.

It is also clear that alterations in the expression of MHC molecules and CIITA, a transcriptional regulator of MHC-II peptide complexes, can influence the immune response against tumours. Downregulation of MHC-II molecules on tumour cells is associated with poor prognosis in cancer patients (Walsh et al., 2009), highlighting the importance of normal expression of immune-related molecules in the tumour microenvironment. A key finding of this study is that EGFR TKIs and EGFR-blocking antibodies augmented the expression of MHC-II molecules on the HNSCC cells, and consequently enhanced EGFR875–889-specific CD4 T-cell recognition against the HNSCC cells. A recent study suggested that these features were due to the key role of EGFR in regulating CIITA expression and function, which is attenuated by EGFR activation but is increased when EGFR is inhibited by EGFR TKIs and blocking antibodies (Pollack et al., 2011). Furthermore, as previously reported (Anido et al., 2003), we also observed that EGFR expression on tumour cells remains at similar levels following EGFR blockade (data not shown). Thus, EGFR inhibitors could be used as immune modulators to enhance the expression of MHC-II molecules on tumour cells, in addition to their original intended function of suppressing proliferation and survival signals derived from EGFR.

### Table 2. Assessment of T-cell responses to the EGFR875–889 peptide in HNSCC patients and healthy donors

| No. | Sex | Age (y) | Pathological stage | Primary site | No antigen (IFN-γ, pg/ml) | No antigen (GM-CSF, pg/ml) |
|-----|-----|--------|-------------------|-------------|--------------------------|--------------------------|
| 1   | M   | 69     | 61 T2N2M0         | Larynx      | < 603 ± 199               | < 195 ± 45               |
| 2   | F   | 73     | 72 T2N1M0         | Oropharynx  | < 294 ± 181               | < 189 ± 47               |
| 3   | F   | 76     | 73 T2N2M0         | Larynx      | < 703 ± 978               | < 125 ± 83               |
| 4   | M   | 61     | 61 T2N2M0         | Oropharynx  | < 358 ± 200               | < 151 ± 55               |
| 5   | F   | 49     | 49 T2N2M0         | Oropharynx  | < 688 ± 351               | < 306 ± 177              |
| 6   | M   | 29     | Normal volunteer  | Oropharynx  | < 556 ± 87                | < 177 ± 38               |
| 7   | F   | 42     | Normal volunteer  | Oropharynx  | < 778 ± 51                | < 313 ± 130              |

<: less than the lower limit of detection (mean <30 pg/ml). No. 1–5 are HNSCC patients and No. 6 and 7 are healthy donors. IL-4, IL-5, IL-17, and IL-10 are not detected in all patients and healthy donors.

![Table 2](https://via.placeholder.com/150)
In summary, we have identified a novel CD4 T-cell epitope from EGFR (EGFR672–889) that elicits effective antitumour T-cell responses against HER family and c-MET-expressing tumours such as HNSCC. In addition, enhancing tumour MHC-II expression by EGFR inhibitors increased the ability of EGFR-reactive CD4 T cells to recognise and kill tumour cells. These observations should enable implementing a strategy for a combined immune-targeted approach to generate effective antitumour therapies and prevent tumour immune evasion.

ACKNOWLEDGEMENTS

We thank Dr Syunsuke Yanoma (Yokohama tsurugaimae Hospital) for providing the HNSCC cell line. This study was supported by JSPS KAKENHI Grant Number 24791735 and 25460430. Esteban Celis is supported by NIH grants R01CA136828 and R01CA157303.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

AUTHOR CONTRIBUTIONS

TK carried out and participated in all of the studies. TK, YM, KO, NA, SK, and YH have made substantial contributions to acquisition of the results. TK provided the clinical samples. EC and HK designed, supervised and coordinated the study, and prepared the manuscript. All authors read and approved the final manuscript.

REFERENCES

Anido J, Matar P, Albarnell J, Guzman M, Rojo F, Arribas J, Averbuch S, Baselga J (2003) ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signalling in HER2-overexpressing breast cancer cells. Clin Cancer Res 9(4): 1274–1283.

Bell DW, Gore I, Okimoto RA, Godin-Heymann N, Sordella R, Mullloy R, Sharma SV, Brannigan BW, Mohapatra G, Settleman J, Haber DA (2005) Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 37(12): 1315–1316.

Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufiyan H, Amellal N, RowinskyEK, Ang KK (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354(6): 567–578.

Chuang HC, Huang CC, Chien CY, Chuang JH (2012) Toll-like receptor 3-mediated tumour invasion in head and neck cancer. Oral Oncol 48(3): 226–232.

Del Vecchio CA, Jensen KC, Nitta RT, Page M, Giacomini CP, Wong AB (2012) Epidermal growth factor receptor variant III contributes to cancer stem cell phenotypes in invasive breast carcinoma. Cancer Res 72(10): 2657–2671.

Diaz Jr LA, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Boizic I, Reiter JG, Nowak MA, Kinzler KW, Oliner KS, Vogelstein B (2012) The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486(7404): 537–540.

Filippazzi P, Pilla L, Mariani L, Patuzzo R, Castelli C, Camisaschi C, Mauriuchi A, Cova A, Ragamonti G, Giardono F, Di Florio A, Asilom M, Frati P, Sovenza G, Squarca P, Maio M, Danielli R, Chiaroni-Sileni V, Villa A, Lombardo C, Tragni G, Santiniam M, Parmiani G, Rivoltini L (2012) Limited induction of tumour cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides. Clin Cancer Res 18(23): 6485–6496.

Giuntoli 2nd RL, Lu J, Kobayashi H, Kennedy R, Celis E (2002) Direct costimulation of tumour-reactive CTL by helper T cells potentiates their proliferation, survival, and effector function. Clin Cancer Res 8(3): 922–931.

Grovold LM, Kim J, Holst MR, Knudsen SL, Grandal MV, van Deurs B (2012) EGFR receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells. Cell Signal 24(1): 296–301.

Hahn S, Gehri R, Erb P (1995) Mechanism and biological signification of CD4-mediated cytotoxicity. Immunol Rev 146: 57–79.

Hayashi S, Kumai T, Matsuda Y, Aoki N, Sato K, Kimura S, Kitada M, Tateno M, Celis E, Kobayashi H (2011) Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer. J Transl Med 9: 191.

Huang S, Li C, Armstrong EA, Peet CR, Saker J, Amler LC, Sliwkowski MX, Harari PM (2013) Dual Targeting of EGFR and HER3 with MEHD7945A Overcomes Acquired Resistance to EGFR Inhibitors and Radiation. Cancer Res 73(2): 824–833.

Katayama A, Takahara M, Kasube K, Nagato T, Kuniibe I, Katada A, Hayashi T, Harabuchi Y (2011) Expression of B7-H3 in hypopharyngeal squamous cell carcinoma as a predictive indicator for tumour metastasis and prognosis. Int J Oncol 38(5): 1219–1226.

Kobayashi H, Celis E (2008) Peptide epitope identification for tumour-reactive CD4 T cells. Curr Opin Immunol 20(2): 221–227.

Kobayashi H, Wood M, Song Y, Appella E, Celis E (2000) Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumour antigen. Cancer Res 60(18): 5228–5236.

Kraus MH, Issing W, Miki T, Popescu NC, Aaronson SA (1989) Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumours. Proc Natl Acad Sci USA 86(23): 9193–9197.

Learn CA, Hartzell TL, Wikstrand CJ, Archer GE, Rich JN, Friedman AH, Friedman HS, Bignier DD, Sampson JH (2004) Resistance to tyrosine kinase inhibitor by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin Cancer Res 10(9): 3216–3224.

Michiels S, Le Maitre A, Buyse M, Burzykowski T, Maillard E, Bogaerts J, Michiels C, Grandis JR (2013) c-Src Activation Mediates Erlotinib Resistance in Lung Cancer. J Clin Oncol 31(2): 380–392.

Panina-Bordignon P, Tan A, Termietzchen A, Demotz S, Corradin G, Panina-Bordignon P, Tan A, Termietzchen A, Demotz S, Corradin G (2005) Identification of epitope structures for tumour-reactive CD4-mediated cytotoxicity. Nat Med 11(11): 1239–1246.

Pollack JP, Sapkota B, Carter TJ, Kaelin WG, III, Brugarolas J, Folkman J, Pignol JP (2009) Sorrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. Lancet Oncol 10(4): 341–350.

Shomura H, Shichijo S, Matsueda S, Kawakami T, Sato Y, Todo S, Itoh K (2004) Identification of epidermal growth factor receptor-derived peptide epitope as immunotherapeutic targets for lung cancer. J Biol Chem 279(10): 9390–9396.

Vertuani S, Triulzi C, Roos AK, Charo J, Norell H, Lemonnier F, Pisa P, Vertuani S, Triulzi C, Roos AK, Charo J, Norell H, Lemonnier F, Pisa P (2004) Overcomes Acquired Resistance to EGFR Inhibitors and Radiation. Cancer Res 64(22): 5489–5498.

Watanabe H, Chihana J, Iwata Y, Kishimoto T, Hayashi T, Tanaka H, Kagami K, Yamauchi K, Saito T, Kato H, Ueno N, Nishio M, Akiyama T (2006) Overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. Cancer Res 66(17): 5935–5944.

Shomura H, Shichijo S, Matsueda S, Kawakami T, Sato Y, Todo S, Itoh K (2004) Identification of epidermal growth factor receptor-derived peptides immunogenic for HLA-A2 (+) cancer patients. Br J Cancer 90(8): 1563–1571.

Soulieudes D, Senzer NN, Vokes EE, Hidalgo M, Agrawala SS, Slui LL (2004) Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 22(1): 77–85.

Southwood S, Sidney J, Kondo A, del Guercio MF, Appella E, Hoffman S, Kudo RT, Chesnut RW, Grey HM, Sette A (1998) Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 160(7): 3363–3373.

Stabile LP, He G, Liu VW, Henry C, Cubis CT, Joyce S, Quensel KM, Siegfried JM, Grandis JR (2013) c-Src Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating c-Met. Clin Cancer Res 19(20): 3902–3912.

Suda K, Murakami I, Katayama T, Tomizawa K, Osada H, Sekido Y, Maehara Y, Yatabe Y, Mitsudomi T (2010) Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res 16(22): 5489–5498.

Vertuani S, Triulzi C, Roos AK, Charo J, Norell H, Lemonnier F, Pisa P, Seliger B, Kiessling R (2009) HER-2/neu mediated down-regulation of
MHC class I antigen processing prevents CTL-mediated tumour recognition upon DNA vaccination in HLA-A2 transgenic mice. Cancer Immunol Immunother 58(5): 653–664.

Walsh MD, Dent OF, Young JP, Wright CM, Barker MA, Leggett BA, Bokey L, Chapuis PH, Jass JR, Macdonald GA (2009) HLA-DR expression is associated with better prognosis in sporadic Australian clinicopathological Stage C colorectal cancers. Int J Cancer 125(5): 1231–1237.

Wheeler S, Siwak DR, Chai R, LaValle C, Seethala RR, Wang L, Cieply K, Sherer C, Joy C, Mills GB, Argris A, Siegfried JM, Grandis JR, Egloff AM (2012) Tumour epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma. Clin Cancer Res 18(8): 2278–2289.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.

Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)